Chemokine receptor–targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG.

MLA

Kosmala, Aleksander, et al. “Chemokine Receptor–targeted PET/CT Provides Superior Diagnostic Performance in Newly Diagnosed Marginal Zone Lymphoma Patients: A Head-to-Head Comparison with [18F]FDG.” European Journal of Nuclear Medicine & Molecular Imaging, vol. 51, no. 3, Feb. 2024, pp. 749–55. EBSCOhost, https://doi.org/10.1007/s00259-023-06489-6.

APA

Kosmala, A., Duell, J., Schneid, S., Serfling, S. E., Higuchi, T., Weich, A., Lapa, C., Hartrampf, P. E., Raderer, M., Einsele, H., Buck, A. K., Topp, M. S., Schlötelburg, W., & Werner, R. A. (2024). Chemokine receptor–targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG. European Journal of Nuclear Medicine & Molecular Imaging, 51(3), 749–755. https://doi.org/10.1007/s00259-023-06489-6

Chicago

Kosmala, Aleksander, Johannes Duell, Simone Schneid, Sebastian E. Serfling, Takahiro Higuchi, Alexander Weich, Constantin Lapa, et al. 2024. “Chemokine Receptor–targeted PET/CT Provides Superior Diagnostic Performance in Newly Diagnosed Marginal Zone Lymphoma Patients: A Head-to-Head Comparison with [18F]FDG.” European Journal of Nuclear Medicine & Molecular Imaging 51 (3): 749–55. doi:10.1007/s00259-023-06489-6.